Table 2.
Primary BSI, Secondary BSI and CLABSI rates per each phase
| Phase | Admissions | Patient-days | CVC-days | Mean CVC-utilization ratio | Total BSI episodes | Primary BSI (no CVC) | Secondary BSI (per 1,000 Patient- days) | CLABSI [mean CLABSI per 1,000 CVC-days*] |
|---|---|---|---|---|---|---|---|---|
| 1 |
1,354 |
7,604 |
6,045 |
0.79 ± 0.07 |
37 |
1 |
12 (1. 58) |
24 [4.00 (1.94-6.06)] |
| 2 |
1,571 |
7,882 |
6,399 |
0.80 ± 0.11 |
33 |
6 |
15 (1.90) |
12 [1.81 (0.46-3.17)] |
| 3 |
1,439 |
7,615 |
6,023 |
0.78 ± 0.10 |
44 |
0 |
28 (3.68) |
16 [2.73 (1.17-4.29)] |
| Total | 4,364 | 23,101 | 18,467 | 0.79 ± 0.09 | 114 | 7 | 55 (2.38) | 52 [2.85 (1.97-3.72)] |
*Incidence Rate Ratio (95% Confidence Interval) and p-value (Poisson regression).
In the phase 2 compared to phase 1: 0.49 (0.24-0.98), p = 0.043.
In the phase 3 compared to phase 1: 0.67 (0.36-1.26), p = 0.212.
In the phase 3 compared to phase 2: 1.37 (0.65-2.89), p = 0.413.